论文部分内容阅读
目的：探讨从细胞的蛋白水平确定喉癌手术的安全切缘范围。方法：采用免疫组化LSAB或SABC方法，对36例原发性喉癌的三组标本（喉癌组，近癌旁组，远癌旁组）行5种抗体（p16、p21，TGF-β1，PCNA，EGFR）检测。结果：5种抗体在喉癌组表达阳性率分别与两边缘组阳性率差异非常显著（P＜0．01）或差异显著（P＜0．05），而近癌旁组与远癌旁组阳性率之间差异均无显著差异（P＞0．05），5种抗体在高分化组与低分化组阳性率差异显著（均为P＜0．05），PCNA在是否有颈淋巴结转移组之间的阳性率表达差异显著（P＜0．05）。全部病例手术切缘大于5mm，复发率3％。结论：结合临床从细胞的蛋白水平证实喉癌的手术切缘5mm是安全的。
OBJECTIVE: To determine the safety margin of laryngeal cancer surgery based on cellular protein levels. Methods: Immunohistochemical LSAB or SABC method was used to detect the expression of 5 kinds of antibodies (p16, p21, TGF-β1) in 36 cases of primary laryngeal cancer (laryngeal cancer group, near-cancer adjacent group, , PCNA, EGFR). Results: The positive rate of the five kinds of antibodies in laryngeal carcinoma group was significantly different from that of the two marginal groups (P <0.01) or significant difference (P <0.05) (P> 0.05). There was significant difference in the positive rates of five antibodies between well-differentiated and poorly-differentiated groups (all P <0.05). The positive rate of PCNA in cervical lymph node metastasis (P <0.05). Surgical margins of all cases greater than 5mm, the recurrence rate of 3%. Conclusion: It is safe to confirm that the surgical margin of laryngeal cancer is 5mm in combination with the clinical level of cellular protein.